Prostaglandins and breast cancer.

No abstract is available for this paper.

• Publication year

  1977

• Venue

  The Lancet

• Publication date

  1977-09-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(77)92496-5PMID 71446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of bone destruction in the development of skeletal metastases

  1976cited by this paper
• Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins

  1976cited by this paper
• Bone destruction by breast tumours.

  1976cited by this paper
• Prostaglandin synthesis inhibition: Effect on bone changes and sarcoma tumor induction in balb/c mice

  1975cited by this paper
• Subversion of immune system by tumor cells and role of prostaglandins.

  1975cited by this paper
• Metabolism of prostaglandins A1 and E1 in man.

  1975cited by this paper
• Hypercalcemia and tumor-prostaglandins: the VX2 carcinoma model in the rabbit.

  1975cited by this paper
• Breast cancer, prostaglandins, and bone metastases.

  1975cited by this paper
• Preliminary experience of bone scanning with 99mTc‐labelled polyphosphate in malignant disease

  1974cited by this paper
• Proceedings: Comparison of 99Tc-labelled polyphosphate, pyrophosphate and ethane hydroxydiphosphonate in patients with skeletal metastases.

  1974cited by this paper
• The Inhibition by Aspirin and Indomethacin of Osteolytic Tumour Deposits and Hypercalcaemia in Rats with Walker Tumour, and its Possible Application to Human Breast Cancer

  1973cited by this paper
• Prostaglandin E2 and gastric acid secretion in man

  1973cited by this paper
• Platelet—tumor‐cell interactions in mice. The role of platelets in the spread of malignant disease

  1973cited by this paper
• Improved purification and chromatography of extracts containing prostaglandins.

  1972cited by this paper
• Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

  1971cited by this paper
• Extraction of Prostaglandins from Human Blood

  1971cited by this paper
• Prostaglandins released by the Spleen

  1968cited by this paper
• PROSTAGLANDINS AND RELATED FACTORS: XIX. THIN-LAYER CHROMATOGRAPHY OF PROSTAGLANDINS.

  1964cited by this paper
• Sinus histiocytosis of lymph nodes in cancer.

  1958cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• Toward Multitasking Pharmacological COX-Targeting Agents: Non-Steroidal Anti-Inflammatory Prodrugs with Antiproliferative Effects

  2021cites this paper
• Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study

  2020cites this paper
• In situ DESI - MSI lipidomic profiles of breast cancer molecular subtypes and precursor lesions.

  2020cites this paper
• Low-Dose Aspirin Use Significantly Improves the Survival of Late-Stage NPC: A Propensity Score-Matched Cohort Study in Taiwan

  2020cites this paper
• Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways.

  2019cites this paper
• Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study

  2019cites this paper
• A JOURNEY OF CELECOXIB FROM PAIN TO CANCER.

  2019cites this paper
• Non-hormonal Chemoprevention

  2018cites this paper
• The impact of aspirin use on breast cancer subtype and clinical course.

  2018cites this paper
• Comparative pharmacokinetics study of anastrozole after single administration and combination with celecoxib

  2018cites this paper
• Targeting lipid mediators in cancer biology

  2018cites this paper
• Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer

  2017cites this paper
• Aspirin use is associated with lower mammographic density in a large screening cohort

  2017cites this paper
• Role of Aspirin in Breast Cancer Survival

  2017cites this paper
• COX-2 inhibitors: a novel strategy in the management of breast cancer.

  2016cites this paper
• Terpenoids Isolated From the Shoot of Plectranthus hadiensis Induces Apoptosis in Human Colon Cancer Cells Via the Mitochondria-Dependent Pathway

  2015cites this paper
• Cyclooxygenase-2 Polymorphisms and Breast Cancer Associated Risk in Pakistani Patients

  2014cites this paper
• A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer

  2013cites this paper
• Pharmacologic Interventions with NSAIDs

  2013cites this paper
• Nutrient intake and nutrient patterns and risk of lung cancer among heavy smokers: results from the COSMOS screening study with annual low-dose CT

  2013cites this paper
• The Extrathyronine Actions of Iodine as Antioxidant, Apoptotic, and Differentiation Factor in Various Tissues

  2013cites this paper
• COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients

  2012cites this paper
• CFTR negatively regulates cyclooxygenase‐2‐PGE2 positive feedback loop in inflammation

  2012cites this paper
• Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.

  2012cites this paper
• Suppression of lipopolysaccharide and galactosamine-induced hepatic inflammation by red grape pomace.

  2012cites this paper
• Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.

  2011cites this paper
• Prostaglandin E2 EP receptors as therapeutic targets in breast cancer

  2011cites this paper
• Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.

  2011cites this paper
• Iodine in Mammary and Prostate Pathologies

  2011cites this paper
• Caffeic Acid, a versatile pharmacophore: an overview.

  2011cites this paper
• Aspirin intake and survival after breast cancer.

  2010cites this paper
• Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function

  2009cites this paper
• A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer.

  2009cites this paper
• Fighting Cancer with Red Wine? Molecular Mechanisms of Resveratrol

  2009cites this paper
• Is Iodine an Antioxidant and Antiproliferative Agent for theMammary and Prostate Glands

  2009cites this paper
• Neoadjuvant therapy with celecoxib to women with early stage breast cancer.

  2008cites this paper
• Nimesulide - Actions and Uses

  2008cites this paper
• Cyclooxygenase II:A Molecular Target for Colorectal Cancer Prevention and Treatment?

  2007cites this paper
• Regulation of Cyclooxygenase-2 by Environmental and Dietary Factors

  2007cites this paper
• COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer.

  2006cites this paper
• Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC.

  2006cites this paper
• HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.

  2006cites this paper
• NSAID use and survival after breast cancer diagnosis in post-menopausal women

  2006cites this paper
• Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line.

  2006cites this paper
• Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways

  2006cites this paper
• Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.

  2006cites this paper
• Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

  2005cites this paper
• Inhibidores de la ciclooxigenasa-2 en la prevención del cáncer

  2005cites this paper
• Cyclooxygenase-2 Expression in Postmastectomy Chest Wall Relapse

  2005cites this paper
• Inhibition by indomethacin of spontaneous mammary tumorigenesis in SHN mice

  2005cites this paper
• IMMUNOHISTOCHEMICAL LOCALIZATION OF COX2 IN CELLS OF MAMMARY ADENOCARCINOMAS IN BITCHES AS RELATED TO TUMOUR MALIGNANCY GRADE

  2005cites this paper
• Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: Diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2

  2005cites this paper
• Cytokine targeted treatments for lung cancer.

  2005cites this paper
• Prognostic significance of cyclooxygenase-2 in breast and esophageal carcinoma

  2005cites this paper
• Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells

  2005cites this paper
• [COX-2 inhibitors in cancer prevention].

  2005cites this paper
• Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.

  2005cites this paper
• The discovery, development and novel actions of nimesulide

  2005cites this paper
• Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer

  2005cites this paper
• A high level of prostaglandin E2 (PGE2) in the portal vein suppresses liver-associated immunity and promotes liver metastases

  2004cites this paper
• Proceedings of the British Pharmacological Society

  2004cites this paper
• Synergy between Celecoxib and Radiotherapy Results from Inhibition of Cyclooxygenase-2-Derived Prostaglandin E2, a Survival Factor for Tumor and Associated Vasculature

  2004cites this paper
• Regulation of interleukin‐12 gene expression and its anti‐tumor activities by prostaglandin E2 derived from mammary carcinomas

  2004cites this paper
• Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients

  2004cites this paper
• The role of COX-2 inhibition in breast cancer treatment and prevention.

  2004cites this paper
• Clinical value of cyclooxygenase-2 expression in human breast carcinoma.

  2004cites this paper
• COX-2 Inhibitors for the Prevention of Breast Cancer

  2004cites this paper
• Arachidonic acid metabolic profiles in human meningiomas and gliomas

  2004cites this paper
• Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1

  2003cites this paper
• Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival

  2003cites this paper
• Dietary Fatty Acids, COX-2 Blockade, and Carcinogenesis

  2003cites this paper
• Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases.

  2003cites this paper
• Selective Cyclooxygenase‐2 Inhibition: A Target in Cancer Prevention and Treatment

  2003cites this paper
• Chemoprevention of Breast Cancer by Nonsteroidal Anti-Inflammatory Drugs and Selective COX-2 Blockade in Animals

  2003cites this paper
• Renal Cell Carcinoma Induces Prostaglandin E2 and T-Helper Type 2 Cytokine Production in Peripheral Blood Mononuclear Cells

  2003cites this paper
• The role of COX-2 in breast and cervical cancer.

  2003cites this paper
• PPARδ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells

  2003cites this paper
• Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis

  2003cites this paper
• The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines.

  2003cites this paper
• Heterodimer receptorów HER 2 / HER 3 , autokrynne hereguliny i cyklooksygenaza 2 a dzia 3 anie Herceptyny Heterodimer of HER 2 / HER 3 receptors , autocrine heregulins and cyclooxygenase 2 , and Herceptin effects

  2003cites this paper
• Expression of Cyclooxygenase-1 and -2 in Human Breast Cancer

  2003cites this paper
• PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells.

  2003cites this paper
• The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

  2003cites this paper
• Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer.

  2003cites this paper
• Involvement of Cyclo‐Oxygenase‐2 in Osteoclast Formation and Bone Destruction in Bone Metastasis of Mammary Carcinoma Cell Lines

  2002cites this paper
• NSAIDS in Dermatologic Therapy: Review and Preview

  2002cites this paper
• Aromatase and Prostaglandin Inter-Relationships in Breast Adipose Tissue: Significance for Breast Cancer Development

  2002cites this paper
• Cyclooxygenase Inhibitors Block Cell Growth, Increase Ceramide and Inhibit Cell Cycle

  2002cites this paper
• Progress in breast cancer chemoprevention.

  2002cites this paper
• Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.

  2002cites this paper
• Celecoxib: a specific COX-2 inhibitor with anticancer properties.

  2002cites this paper
• Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.

  2002cites this paper
• NSAIDs in Dermatologic Therapy: Review and Preview

  2002cites this paper
• Cyclo-Oxygenase Inhibitors and Thromboxane Synthase Inhibitors Differentially Regulate Migration Arrest, Growth Inhibition and Apoptosis in Human Glioma Cells

  2002cites this paper
• Aspirin‐Induced Inhibition of Ovarian Tumor Cell Growth

  2002cites this paper
• The role of cyclooxygenase inhibitors in cancer prevention.

  2002cites this paper
• Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.

  2002cites this paper
• A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer.

  2002cites this paper
• Increased cyclooxygenase‐2 (cox‐2) expression and activity in a murine model of metastatic breast cancer

  2001cites this paper
• Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.

  2001cites this paper